EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction: Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo

Ayako Sedohara, Tomohiko Koibuchi, Makoto Yamagishi, Michiko Koga, Kotaro Arizono, Kazuhiko Ikeuchi, Tadashi Kikuchi, Makoto Saito, Eisuke Adachi, Takeya Tsutsumi, Daisuke Honma, Kazushi Araki und 2 weitere

Frontiers in Microbiology · 30.10.2026 · 17

DOI: 10.3389/fmicb.2026.2009976 ↗

Kurz gefasst

Korrektur in der Zeitschrift Frontiers in Microbiology, online erschienen am 30.10.2026. Verfasst von Ayako Sedohara und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[This corrects the article DOI: 10.3389/fmicb.2025.1581330.].

Schlagwörter

Stichwörter der Autor:innen

E7438EZH1/2 dual inhibitorGSK126HIV-1 reservoirlatency reversing agentssuberoylanilide hydroxamic acidvalemetostat

Autor:innen und Institutionen

  • Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
  • Department of Infectious Disease and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
  • Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Department of Infectious Diseases, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Modality Research Laboratories III, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
  • Early Clinical Development Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.

Zitieren

APA

Sedohara, A., Koibuchi, T., Yamagishi, M., Koga, M., Arizono, K., Ikeuchi, K., Kikuchi, T., Saito, M., Adachi, E., Tsutsumi, T., Honma, D., Araki, K., Uchimaru, K., & Yotsuyanagi, H. (2026). Correction: Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.2009976

Vancouver

Sedohara A, Koibuchi T, Yamagishi M, Koga M, Arizono K, Ikeuchi K, et al. Correction: Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.2009976

BibTeX
@article{Sedohara2026,
  author = {Sedohara, Ayako and Koibuchi, Tomohiko and Yamagishi, Makoto and Koga, Michiko and Arizono, Kotaro and Ikeuchi, Kazuhiko and Kikuchi, Tadashi and Saito, Makoto and Adachi, Eisuke and Tsutsumi, Takeya and Honma, Daisuke and Araki, Kazushi and Uchimaru, Kaoru and Yotsuyanagi, Hiroshi},
  title = {Correction: Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.2009976}
}
Kostenlos starten →